Galectins: Double edged swords in the cross-roads of pregnancy complications and female reproductive tract inflammation and neoplasma by Than, Nándor Gábor et al.
181
© 2015 The Korean Society of Pathologists/The Korean Society for Cytopathology
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ 
by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
pISSN 2383-7837
eISSN 2383-7845
Journal of Pathology and Translational Medicine 2015; 49: 181-208
http://dx.doi.org/10.4132/jptm.2015.02.25
▒ REVIEW ▒
Galectins: Double-edged Swords in the Cross-roads of Pregnancy 
Complications and Female Reproductive Tract Inflammation and Neoplasia
Nandor Gabor Than1,2,3,4,5 
Roberto Romero1 · Andrea Balogh1,6 
Eva Karpati3,6 
Salvatore Andrea Mastrolia7,8 
Orna Staretz-Chacham9 
Sinuhe Hahn10 · Offer Erez1,2,7 
Zoltan Papp4 · Chong Jai Kim1,11,12
1Perinatology Research Branch, Eunice  
Kennedy Shriver National Institute of Child Health 
and Human Development, National Institutes 
of Health, Department of Health and Human 
Services, Detroit, MI, USA; 2Department of 
Obstetrics and Gynecology, Wayne State 
University School of Medicine, Detroit, MI, USA; 
3Institute of Enzymology, Research Centre for 
Natural Sciences, Hungarian Academy of 
Sciences Budapest, Budapest, Hungary; 
4Maternity Private Department, Kutvolgyi 
Clinical Block, Semmelweis University, Budapest, 
Hangary; 5First Department of Pathology and 
Experimental Cancer Research, Semmelweis 
University, Budapest, Hungary; 6Department of 
Immunology, Eotvos Lorand University, 
Budapest, Hungary; 7Department of Obstetrics 
and Gynecology, Ben-Gurion University, 
Beer-Sheva, Israel; 8Department of Obstetrics 
and Gynecology, University of Bari Aldo Moro, 
Bari, Italy; 9Department of Neonatology, 
Ben-Gurion University, Beer-Sheva, Israel; 
10Department of Biomedicine, University Hospital 
Basel, Basel, Switzerland; 11Department of 
Pathology, Wayne State University, Detroit, MI, 
USA; 12Department of Pathology, Asan Medical 
Center, University of Ulsan College of Medicine, 
Seoul, Korea
Galectins are an evolutionarily ancient and widely expressed family of lectins that have unique 
glycan-binding characteristics. They are pleiotropic regulators of key biological processes, such 
as cell growth, proliferation, differentiation, apoptosis, signal transduction, and pre-mRNA splic-
ing, as well as homo- and heterotypic cell-cell and cell-extracellular matrix interactions. Galectins 
are also pivotal in immune responses since they regulate host-pathogen interactions, innate and 
adaptive immune responses, acute and chronic inflammation, and immune tolerance. Some ga-
lectins are also central to the regulation of angiogenesis, cell migration and invasion. Expression 
and functional data provide convincing evidence that, due to these functions, galectins play key 
roles in shared and unique pathways of normal embryonic and placental development as well as 
oncodevelopmental processes in tumorigenesis. Therefore, galectins may sometimes act as 
double-edged swords since they have beneficial but also harmful effects for the organism. Re-
cent advances facilitate the use of galectins as biomarkers in obstetrical syndromes and in vari-
ous malignancies, and their therapeutic applications are also under investigation. This review 
provides a general overview of galectins and a focused review of this lectin subfamily in the con-
text of inflammation, infection and tumors of the female reproductive tract as well as in normal 
pregnancies and those complicated by the great obstetrical syndromes.
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INTRODUCTION TO THE GALECTIN FAMILY
More than half of all human proteins are glycosylated,1 and 
glycans are attached to various additional glycoconjugates (e.g. 
glycolipids) besides glycoproteins. Because of the abundance of 
glycans intra- and extracellularly and also their high complexity, 
glycans can store orders of magnitude larger biological informa-
tion than other biomolecules (e.g. nucleic acids and proteins).2,3 
Lectins are sugar-binding proteins, which are not an antibody or 
an enzyme, and can specifically bind glycans without catalyzing 
their modification.3,4 The interactions of lectins with glycans are 
pivotal in the regulation of a wide variety of interactions of cells 
with other cells, the extracellular matrix or pathogens.2-4
Galectins belong to a subfamily of lectins based on their unique 
structural and sugar-binding characteristics, since their carbohy-
drate-recognition domains (CRDs) contain consensus amino acid 
sequences and they specifically bind beta-galactoside–containing 
glycoconjugates.5-8 Galectins are the most widely expressed ani-
mal lectins; they have been found in species ranging from spong-
es to humans.7-9 They regulate a wide variety of key biological 
processes, such as cell growth, proliferation and differentiation, 
apoptosis, signal transduction, pre-mRNA splicing, as well as 
cell-cell and cell-extracellular matrix interactions.2,5-9 Galectins 
are also pivotal in immune responses since they regulate host-
pathogen interactions, acute and chronic inflammation, and im-
mune tolerance (Fig. 1).8,10-13 Moreover, some galectins are cen-
tral to the regulation of angiogenesis in the placenta and in 
tumors.14,15 Interestingly, galectins can have opposing functions, 
and the same galectin can also have varying or contrasting effects 
based on the biological context and the microenvironment since 
their functions depend on the differentiation or activation status 
of the cell, the dynamic changes of their glycan partners on the 
cell surfaces, the redox and oligomerization status of the galec-
tin, or its intra- or extracellular localization.8,11,16,17 Thus, galec-
tins’ double-edged action may sometimes be beneficial or harm-
ful to the organism.
The fundamental functions of galectins indicate that they are 
strongly associated with reproductive functions as well as the es-
tablishment and maintenance of pregnancy.10,18-28 Indeed, some 
galectins are highly expressed at the maternal-fetal interface,10,18-39 
and these are evolutionarily linked to placental evolution in eu-
therian mammals.5,7,9,26,27,40 Moreover, the dysregulated expres-
sion of these galectins in pregnancy complications has been in-
creasingly documented.10,23,32-36,38,41-51 Galectins have also been 
implicated in inflammatory, infectious and malignant diseases of 
the reproductive tracts. Of importance, the same galectins may 
be functional in pathways commonly shared by physiological 
and pathological, placental, and tumor developmental processes 
(e.g. cell invasion, angiogenesis, and immune tolerance). This re-
view aims to give a general overview of galectins and also a fo-
cused review of them in the context of inflammation, infection 
and tumors in the female reproductive tract as well as in normal 
and complicated pregnancies.
Structural features of mammalian galectins
Galectins were originally termed “S-type lectins,” where “S” 
refers to their free cysteine residues.6,8 Galectins or galectin-like 
proteins were also discovered in fungi, viruses, and even plants.8,9 
Because of the diversity between mammalian and non-mamma-
lian galectins, their nomenclature has diverged as mammalian 
galectins have been named using sequential numbering, while 
non-mammalian galectins have retained specific names (Table 1).6 
Nineteen galectins have been identified in mammals to date, 13 
of which were found in humans.9,27 These galectins can be divid-
ed into three structural groups:5-8 (1) “proto-type” galectins (-1, 
-2, -5, -7, -10, -13, -14, -15, -16, -17, -19, -20) contain a single 
CRD of ~130 amino acids, which homodimerize;5-8,52 (2) “tan-
dem-repeat-type” galectins (-4, -6, -8, -9, -12) contain two ho-
mologous CRDs connected by a short linker sequence. These 
may differ in their sugar-binding affinities and enable multiva-
lent binding activity;5-7,52 and (3) “chimera-type” galectin-3, 
which contains a C-terminal CRD and an N-terminal non-lectin 
domain important for multimerization and cross-linking as well 
as functional regulation.5-7,52
Although the amino acid sequences of galectins have diverged 
during evolution, the topologies of their CRDs are very similar, 
often described as “jelly-roll;” these are β-sandwiches consisting 
of five- and six-stranded anti-parallel β-sheets (Fig. 1).6-8,53-55 
Highly conserved in galectin CRDs are eight residues, which are 
involved in glycan-binding by hydrogen-bonds as well as elec-
trostatic and van der Waals interactions.53,55 All galectins specifi-
cally bind beta-galactosides5-8 except galectin-10, which has more 
affinity to beta-mannosides.53 Of interest, some galectins have 
high affinity for poly-N-acetyllactosamine or ABO blood-group 
containing glycans, and the latter is responsible for their hemag-
glutinin activity.52,56-58
Functional characteristics of mammalian galectins
Galectins have multiple functions both inside and outside the 
cell (Table 1).8,59,60 Intracellularly, certain galectins can modulate 
cell growth, differentiation, apoptosis, and migration8,59,60 via 
protein-protein interactions.8,59,60 Some galectins (-1 and -3) 
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shuttle into the nucleus where they function in pre-mRNA splic-
ing.8,59 In spite of the fact that they do not have a secretory signal 
sequence, galectins can be secreted from cells via a non-classical 
pathway, avoiding the endoplasmic reticulum and Golgi appara-
tus, which is characteristic of only a small set of proteins (e.g. 
high-mobility group box 1 protein, interleukin-1β).61 Extracel-
lularly, galectins predominantly localize to lipid rafts on cell sur-
faces8,52,62 where they exert their functions through binding to 
cell-surface or extracellular matrix molecules, which carry their 
glycan ligands.2,7,8,11,13,52,63,64 They can form multivalent galectin-
glycan arrays, so-called lattices, by cross-linking their ligands on 
cell surfaces, and these lattices can organize lipid raft domains and 
modulate cell signaling for cell growth, metabolic functions, cy-
tokine secretion, and survival, as well as many other intracellular 
and extracellular interactions.8,11,13,17,52,65 Some galectins can also 
affect cell adhesion and apoptosis, and activate or inhibit im-
mune responses.8,11,13,63 An interesting trait of galectins is that 
their secretion is heightened upon response to stress conditions 
(e.g. inflammation and infection) and cellular damage (e.g. necro-
sis); therefore, galectins have been implicated as “alarmins” which 
signal tissue damage and elicit effector responses from immune 
cells, thereby promoting the activation and/or resolution of im-
mune responses.12,35,64,66
Expression profile of human galectins
Accumulating evidence in various species shows that galectins 
have distinct but overlapping tissue expression patterns in mam-
mals including humans (Table 1).6,8,27,67,68 Among prototype ga-
lectins, galectin-1 and galectin-3 have a wide expression pattern 
in humans, galectin-1 being the most abundant in the endome-
trium/decidua.8,26,67 Among tandem-repeat-type galectins, ga-
lectin-8 and galectin-9 have a broad and complex expression 
pattern. Alternatively spliced isoforms of galectin-8 are differen-
tially expressed in various tissues8,39,67 similar to galectin-9, 
which is encoded by three genes.67 These galectins are highly ex-
pressed in the female reproductive tract and at the maternal-fetal 
interface.8,10,18-23,25,27,32,34,35,37-39,69 Some galectins (-2, -4, -5, -6, -7, 
-12) have more restricted tissue distribution.8,67 Of note, the ex-
pression of galectins in the chromosome 19 cluster is very re-
stricted. Among these, galectin-10 is expressed in T regulatory 
(Treg) cells, as well as eosinophil and basophil lineages, and forms 
the so-called Charcot-Leyden crystals at sites of eosinophil-asso-
ciated inflammation.53,70 The expression of galectin-13, -14 and 
-16 is predominant in the placenta, while galectin-17 expression 
is low in any tissues.27,29,67,71 Interestingly, these galectins (-10, 
-13, -14, -16, -17), which are expressed from the chromosome 
19 cluster, emerged via birth-and-death evolution in anthropoid 
primates and may regulate unique aspects of pregnancies, in-
cluding maternal-fetal immune regulation and tolerance in these 
species.16,27,72
GALECTINS IN INFECTION AND 
INFLAMMATION OF THE FEMALE 
REPRODUCTIVE TRACT
Due to the multiple functions of galectins, they have been 
implicated in pathways and processes fundamental for reproduc-
tive functions in both the pregnant and non-pregnant state. Data 
on the expression profile and functions of galectins regarding fe-
male reproductive tissues has recently emerged. Accordingly, a 
growing body of evidence suggests that galectins play important 
roles in immune responses in inflammatory and infectious diseas-
es and in the development of various tumors of the female repro-
ductive tract.
Galectins in infection of the female reproductive tract
Recent evidence suggests that the outcome of infection is also 
significantly influenced by galectins (Fig. 1) as these glycan-
binding proteins acts as regulators of host-pathogen interac-
tions.12 Similar to alarmins, upon tissue damage and/or prolonged 
infection, cytosolic galectins can be passively released from dying 
cells or actively secreted by inflammation-activated cells through 
the non-classical ‘leaderless’ secretory pathway.12 Once exported, 
galectins act as soluble or membrane-bound ‘damage associated 
molecular patterns’12,66 or ‘pathogen associated molecular pat-
terns.’ The latter, due to their CRDs, can specifically recognize 
pathogen cell surface antigens like pattern recognition recep-
tors.12,66,73 Indeed, various galectins have been shown to bind a 
wide range of pathogens, which display their ligands on the sur-
faces, such as Gram-positive bacteria (e.g. Streptococcus pneumoni-
ae), Gram-negative bacteria (e.g. Klebsiella pneumoniae, Neisseria 
meningitidis, Neisseria gonorrhoeae, Haemophilus influenzae, Pseudomo-
nas aeruginosa, Porphyromonas gingivalis, and Escherichia coli), envel-
oped viruses (Nipah and Hendra paramyxoviruses, human im-
munodeficiency virus [HIV]-1, and influenza virus A), fungi 
(Candida albicans) and parasites (Toxoplasma gondii, Leishmania 
major, Schistosoma mansoni, Trypanosoma cruzi, and Trichomonas vag-
inalis).12,74-82
It is interesting that the co-evolution of microbes and host gly-
cocalyx components is a continuously ongoing process, and the 
evolutionary arms race, the “Red Queen effect,” has strongly im-
pacted pathogenic and invasive properties of those microbes in 
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relation to glycocalyx components that now infect our species.73,83 
For example, it has been observed that galectin-3 provides ad-
vantage for Helicobacter pylori in binding to gastric epithelial cells, 
and thus, enhances the rate of infection.78 Similarly, galectin-1 
increases the spread of human T-cell leukemia virus type I by 
stabilizing both virus-cell and uninfected-infected T cell interac-
tions.79 Interestingly, due to their ligand-binding specificity, ga-
lectin-1, but not galectin-3, can influence the sexual transmis-
sion of HIV-1 through the increase of viral adsorption kinetics on 
monocyte-derived macrophages.77,84 Based on this data, the prog-
ress of microbial infections seems to depend on the expression 
and localization of various galectins in the route of infection.
The most studied galectin in infections of the female repro-
ductive tract is galectin-3. It is expressed on the apical side of the 
non-ciliated epithelial cells in the Fallopian tube and can bind 
the lipooligosaccharides on Neisseria gonorrhoeae. Since galectin-3 
participates in several endocytotic processes, such as its own re-
uptake, it can facilitate the invasion of human epithelial cells by 
gonococci.74 Interestingly, in response to gonococcal infection, 
tumor necrosis factor α production increases in the Fallopian 
Fig. 1. Galectins in inflammation and infection. The effects and expression changes of galectins in immune cells are depicted around the 
three-dimensional model of galectin-1 (Protein Data Bank accession number: 1GZW).35,55 Galectins’ effects are biological-context and micro-
environment dependent and relate to the differentiation or activation status of the cell, the dynamic changes of the glycan partners of galec-
tins on cell surfaces, the redox and oligomerization status of the galectin, or its intracellular or extracellular localization. ECM, extracellular 
matrix; HIV-1, human immunodeficiency virus 1; iNOS, inducible nitric oxide synthase; IFN, interferon; IL, interleukin; LPS, lipopolysaccha-
ride; NK, natural killer; TNF, tumor necrosis factor. Parts of the figure are adapted from Than et al. Trends Endocrinol Metab 2012; 23: 23-31, 
with permission of Elsevier.16 
T cells
Galectin-1
↑ IL-4, IL-5, IL-10 production
↑ Treg formation
↑ Expression and release in HTLV-1 infected cells
↑ Activation of FoxP3+ cells
↓ Apoptosis (thymocytes, activated Th1/Th17 cells)
↓ Cell proliferation
↓ Pro-inflammatory cytokine production
↓ Cell adhesion to ECM
Galectin-2
↑ Apoptosis
↑ IL-5, IL-10 production
↓ Pro-inflammatory cytokine production
Galectin-3
↑ Cell proliferation
↑ Apoptosis (extracellularly)
↑ Expression in HIV-1 infected cells
↓ Apoptosis (intracellularly)
↓ IFNγ production
↓ Adhesion of thymocytes to ECM
Galectin-4
↑ IL-6 production
Galectin-8
↑ Activation
Galectin-9
↑ Apoptosis (thymocytes)
↓ IFNγ production
Galectins-13, -14, -16, -17
↑ Apoptosis (activated T cells)
B cells
Galectin-1
↑ Expression upon activation
↑ Antibody production
↑ Plasma cell differentiation
↑ Plasma cell survival
↑ B cell development
Galectin-3
↑ Plasma cell differentiation
↓ IL-4 induced survival
Galectin-8
↑ Antibody production
↑ Plasma cell differentiation
Eosinophils
Galectin-1
↓ Migration
Galectin-3
↓ IL-5 production
Galectin-9
↑ Chemotaxis
↑ Superoxide generation
↑ Degranulation
Galectin-10
↑ Secretion upon activation
Neutrophils
Galectin-1
↑ NADPH oxidase activity
↓ Chemotaxis
↓ Extravasation
Galectin-3
↑ Adhesion to laminin
↑ Adhesion to fibronectin
↑ IL-8 production
↑ Chemotaxis
↑ Extravasation in response to infection
↑ NADPH oxidase activity
Galectin-8
↑ NADPH oxidase activity
Basophils
Galectin-1
↓ Degranulation
Galectin-3
↑ Activation
NK and NKT cells
Galectin-1
↑ NK cell mediated immunosuppression
Galectin-3
↓ Activation
Galectin-9
↑ Apoptosis
↑ Activation
Macrophages
Galectin-1
↑ Viral (HIV-1) adsorption
↑ Arginase activity
↓ iNOS activity and NO production
↓ Arachidonic acid release
Galectin-3
↑ Chemotaxis
↑ LPS induced IL-1β secretion
↑ Phagocytosis
↑ Respiratory burst
↑ Activation and Ca2+ influx
↑ Phagosome formation
↓ LPS induced IL-6, TNFα and INFγ secretion
↓ Apoptosis
Galectin-13
↑ IL-1α and IL-6 production
Dendritic cells
Galectin-1
↑ Maturation
Galectin-3
↑ Expression by T. cruzi infection
Galectin-9
↑ Maturation
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tube and induces apoptosis of cells not protected by galectin-3. 
Since the presence of gonococci is limited mainly to galectin-3–
positive non-ciliated cells, galectin-3 promotes the survival of 
this pathogen.74 The induction of this anti-apoptotic effect of 
galectin-3 can be observed when it is phosphorylated in response 
to infection, which increases the ability of galectin-3 to induce 
arrest in the G1 growth phase85 and to perpetuate the survival 
and proliferation of infected cells.78
Besides galectin-3, galectin-1 and -7 can also bind Trichomonas 
vaginalis. Surprisingly, the interaction of galectin-7 with this 
pathogen is not carbohydrate-mediated, in contrast to galec-
tin-1, which is expressed by human cervical and vaginal epithe-
lial cells, the placenta, as well as endometrial and decidual tis-
sues.80,81 Galectin-1 and -3 are capable of binding purified 
lipophosphoglycan, which covers the whole surface of Trichomon-
as vaginalis.86 Galectin-1 is thought to be a general attachment 
factor for this parasite and promotes the colonization of the fe-
male and male reproductive tracts, which could lead to vaginitis, 
bacterial vaginosis, increased risk of cervical cancer, human pap-
illomavirus and HIV infection in females, endometritis, infertil-
ity, preterm birth, and low birth weight.81 In addition, female 
infants could get infected during birth and then would remain 
symptomless until puberty.87
In contrast to the harmful roles of galectins during Trichomonas 
vaginalis infection, upon invasion of this parasite, vaginal epithe-
lial cells release galectin-1 and -3, and these galectins modulate 
vaginal epithelial cell inflammatory responses by triggering resi-
dent immune cells, and thus, contribute to the elimination of 
this pathogen.81 In addition, secreted galectin-3 initiates the 
trafficking of phagocytic cells to the site of infection by support-
ing neutrophil adhesion to the endothelial cell layer, and this 
also increases its phagocytic activity.78,88
Galectins in inflammation of the female reproductive tract
Among various inflammatory diseases of the female reproduc-
tive tract, endometriosis has been the most studied in regard to 
Table 1. Mammalian galectins
Galectin Species Human tissue and cell localization
Participation in biological processes 
relevant to tumors and pregnancy in mammals
Galectin-1 From fishes Adipose tissue, bone marrow, central nervous system, 
  endocrine glands, endothelia, female and male reproductive      
  systems, immune cells, lymphatic organs, placenta, 
  respiratory system, skin, smooth muscle
Angiogenesis, apoptosis, cell adhesion, 
  proliferation, migration and invasion, inflammation 
  and infection, immune tolerance, immune 
  surveillance
Galectin-2 From fishes Blood, bone marrow, digestive tract, immune cells, 
  lymphatic organs, placenta, urinary tract
Apoptosis, inflammation and infection, 
  tumor cell adhesion
Galectin-3 From fishes Adipose tissue, bone marrow, central nervous system, 
  digestive tract, endocrine glands, female and male 
  reproductive systems, heart muscle, immune cells, 
  lymphatic organs, placenta, respiratory system, skin, 
  smooth muscle, urinary tract
Apoptosis, cell proliferation, migration and 
  invasion, inflammation and infection, 
  immune tolerance, immune surveillance, 
  tumor and immune cell adhesion
Galectin-4 From amphibians Digestive tract, male reproductive system, skin Inflammation, tumor cell adhesion
Galectin-5 Only in rodents - -
Galectin-6 Only in rodents - -
Galectin-7 From mammals Digestive tract, female reproductive system, 
  hearth, lymphatic organs
Apoptosis, cell proliferation
Galectin-8 From amphibians Bone marrow, digestive tract, endocrine glands, 
  female and male reproductive systems, immune cells, 
  lymphatic organs, placenta, urinary tract
Infection, tumor and immune cell adhesion
Galectin-9 From fishes Adipose tissue, bone marrow, digestive tract, 
  endocrine glands, female reproductive system, 
  immune cells, lymphatic organs, placenta, 
  respiratory system, skin, smooth muscle
Apoptosis, cell proliferation, migration, 
  inflammation and infection
Galectin-10 From primates Bone marrow, immune cells, lymphatic organs Inflammation, immune regulation
Galectin-12 From amphibians Adipose tissue, bone marrow, female reproductive system, 
  immune cells
Apoptosis, cell proliferation
Galectin-13 From primates Placenta Apoptosis, immune regulation, immune tolerance
Galectin-14 From primates Placenta Apoptosis, immune regulation, immune tolerance
Galectin-15 Ruminants - -
Galectin-16 From primates Placenta Apoptosis, immune regulation, immune tolerance
Galectin-17 From primates Placenta Apoptosis, immune regulation, immune tolerance
Galectin-19 New World Monkeys - -
Galectin-20 New World Monkeys - -
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galectins. Endometriosis is an inflammatory disease of reproduc-
tive-aged women, and it is strongly related to consequent infer-
tility.89 The pathophysiology of endometriosis involves chronic 
dysregulation of inflammatory and vascular signaling,90 process-
es in which galectins are operational. Not surprisingly, galec-
tin-1 and -3 are overexpressed in various forms of endometriotic 
tissues.91-94 Moreover, higher galectin-3 concentrations are also 
detected in peritoneal fluid samples from women with endome-
triosis than from controls.93 Functionally, it has been shown that 
corticotropin releasing hormone (CRH) and urocortin, two neu-
ropeptides that are also overexpessed in endometriosis, are in-
volved in the up-regulation of galectin-1, acting through CRH 
receptor 1, in a human endometrial adenocarcinoma cell line and 
in mouse macrophages.94 This up-regulation of galectin-1 may 
contribute to T cell apoptosis favoring the establishment, persis-
tence and immune escape of endometriotic foci.90 Moreover, ga-
lectin-1 may promote the vasculogenesis of endometriotic tis-
sues since it orchestrates vascular networks in endometriotic 
lesions as demonstrated in mice with or without galectin-1 defi-
ciency,92 and a neutralizing antibody against galectin-1 reduces 
the size and vascularized area of endometriotic lesions within the 
peritoneal compartment.92
Recent data have suggested that galectin-3 may play a role in 
the development of pain due to endometriosis since it is involved 
in myelin phagocytosis, Wallerian degeneration of neurons, and 
triggers neuronal apoptosis induction after nerve injury.95 In fact, 
galectin-3, overexpressed in endometriotic foci, could induce 
nerve degeneration, since there is a close morphological relation-
ship between nerves and endometriotic foci by means of perineu-
rial and endoneurial invasion, especially in the most painful form 
of the disease.96 Interestingly, neurotrophin, a nerve growth fac-
tor strongly expressed in endometriosis, up-regulates galcetin-3 
expression.91 These data underline the importance of galectin-1 
and -3 in the pathogenesis of endometriosis.
Fig. 2. Galectins in neoplasia of the female reproductive tract. The functional effects of various galectins in tumorigenesis and their expres-
sion changes in certain types of female tract neoplasia are depicted. The effects of galectins are biological-context and microenvironment 
dependent. Galectins’ expression changes can be different according to the stage and type of various neoplasia as well as the type of the 
expressing cell. DC, dendritic cell. 
Galectins’ role in tumorigenesis
Angiogenesis
Galectin-3
↑ Angiogenesis
Tumor invasion
Galectin-1
↑ Tumor transformation
↑ Cancer cell proliferation (intracellularly)
↓ Cancer cell proliferation (extracellularly)
↓↑ Interactions during tumor invasion
Galectin-3
↑ Cell-cell and cell-ECM interactions
↓ Tumorigenicity in the nucleus
Galectin-7
↑ Metastasis via regulating metastatic genes
↑ Resistance to drug induced apoptosis
↑ Cell migration
Galectin-8
↑ Cell adhesion through certain integrins
Galectin-9
↑ Tumor metastasis depending on isoform
Immune tolerance and tumor immune escape
Galectin-1
↑ Apoptosis of activated T cells
↑ Treg and DC activation
Galectins’ expression in tumors
Breast
↑ Galectin-1
↓ Galectin-3
↑ Galectin-7
↑ Galectin-8
↓ Galectin-9
Ovary
↑ Galectin-1
↓ Galectin-3
↑ Galectin-7
Uterus
↑ Galectin-1
↓↑ Galectin-3
↓↑ Galectin-7
Cervix
↑ Galectin-1
↓↑ Galectin-3
↓ Galectin-7
↓ Galectin-9
Galectin-3
↓ Anti-apoptic effect
Galectin-7
↑ Apoptosis of lymphocytes and monocytes
Galectin-9
↑ Treg differentiation
↑ Apoptosis of Th1 and Tc cells
↓ Th17 differentiation
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GALECTINS IN TUMORS OF THE FEMALE 
REPRODUCTIVE TRACT
The multifunctional role of galectins in cell growth, differen-
tiation, apoptosis, adhesion, invasion, and angiogenesis explains 
why they are associated with different tumors. Indeed, many can-
cers have differential galectin expression compared to healthy con-
trols, including tumors of the female reproductive tract (Fig. 2).97 
Of interest, certain galectins have been functionally implicated in 
dysregulated pathways in tumor developmental processes, which 
are physiologically tightly regulated during placental develop-
ment (e.g. invasion, angiogenesis, and immune tolerance).14,16,17,98 
In addition, galectins may also be dysregulated in tumor-associ-
ated stromal cells or endothelial cells,15,99 and their glycan ligand 
expression and/or glycosylation pattern can also be affected.100,101 
Most of these studies focused on galectin-1 and -3, but an in-
creasing number of recent studies also investigated galectin-7, 
-8, and -9.
Galectin-1 is differentially expressed in several tumors in the 
female reproductive tract. An increased expression of galectin-1 
protein is found in endometrial,102,103 breast,104 ovarian,105 and 
cervical106 cancers. The intensity of galectin-1 expression also in-
creases according to the pathologic grade of cervical106 or 
breast104 cancer and correlates with the depth of invasion of the 
cervical cancer and in lymph node metastases.107 In breast cancers, 
not only tumor cells but also cancer-associated stromal cells have 
elevated galectin-1 expression.99 In squamous cell carcinoma 
(SCC) of the uterine cervix, the intracellular expression of galec-
tin-1 in tumor cells is higher than in the tumor-associated stro-
ma, and galectin-1 is an independent prognostic factor associated 
with local recurrence and cancer-specific survival in stage I–II 
cervical cancer patients undergoing definitive radiation thera-
py.108 It has been suggested that galectin-1 mediates radio-resis-
tance through the H-Ras signaling pathway that is involved in 
DNA damage repair in cervical carcinoma cells,109 underlining 
the importance of galectin-1 in tumorigenesis and therapy.
Galectin-3 is down-regulated in cervical carcinomas, and its 
expression is correlated to histopathologic grades.110 It is also 
down-regulated in advanced uterine adenocarcinoma cells com-
pared to normal adjacent endometrial cells.102,103 Moreover, ga-
lectin-3 expression is predominantly detected in the cytoplasm 
and/or nucleus of uterine or breast cancer cells.102,111,112 Of note, 
those uterine endometrioid adenocarcinomas, where galectin-3 
is detected only in the cytoplasm, are characterized by deeper in-
vasion of the myometrium.102 In addition, the neoplastic epithe-
lium within ‘MELF’ (microcystic, elongated, and fragmented 
glands) areas shows a consistent reduction in galectin-3 protein 
expression, often contrasting with the adjacent galectin-3–posi-
tive conventional glands and reactive stromal cells. Conversely, 
intravascular tumor foci often show cytoplasmic and nuclear ga-
lectin-3 immunoreactivity.112 On the contrary, in some ovarian 
and endometrial carcinomas, including clear cell, serous, endo-
metrioid, and mucinous ovarian carcinomas, higher galectin-3 
expression is seen either by immunohistochemistry113-116 or by 
reverse transcription polymerase chain reaction.117 Which bio-
logical functions of galectin-3 are utilized by tumor cells de-
pends on the localization of this galectin: nuclear galectin-3 may 
function in mRNA splicing, cell growth and cell cycle regula-
tion; cytoplasmic galectin-3 may induce apoptosis resistance; 
and secreted galectin-3 modulates cellular adhesion and signal-
ing, immune response, angiogenesis and tumorigenesis by bind-
ing to cell surface glycoconjugates such as laminin, fibronectin, 
collagen I and mucin-1.111,118-121 For example galectin-3 may 
mediate chemoresistance via regulating the cell cycle as respond-
ers to chemotherapy have a higher proliferation activity than 
non-responders. This finding was strengthened by experimental 
results after knocking down galectin-3, which increases the frac-
tion of cells in the S-phase of the cell cycle and decreases the ex-
pression of p27 cyclin dependent kinase inhibitor in clear cell 
carcinoma cell lines.114 Moreover, the ability of galectin-3 to pro-
tect cells against apoptosis induced by various agents, working 
through different mechanisms, suggests that galectin-3 acts in a 
common central pathway of the apoptotic cascade, involving 
protection of mitochondrial integrity and caspase inhibi-
tion.85,122-128 Of importance, a galectin-3 polymorphism, the 
substitution of a proline with histidine (P64H), results in suscep-
tibility to matrix metalloproteinase cleavage and acquisition of 
resistance to drug-induced (e.g. doxorubicin, staurosporine, and 
genistein) apoptosis,129-131 and homozygosity for this H allele is 
associated with increased breast cancer risk.130 On the other 
hand, the Pro64 variant and phosphorylation of galectin-3 at 
Ser6 seems to be important in tumor necrosis factor-related 
apoptosis-inducing ligand (TRAIL)–induced apoptosis of hu-
man breast carcinoma cells.131,132 Interestingly, nicotine induces 
the expression of galectin-3 in breast cancer cells and in primary 
tumors from breast cancer patients through its receptor and 
STAT3 expression, increasing the anti-apoptotic effect of galec-
tin-3, and suggesting detrimental effects of smoking.133
Galectin-7 up-regulation in cervical cancer is associated with 
better overall survival after definitive radiation treatment,134 and 
similar observations were made in other cancers (e.g. urothelial 
and colon), as well.135-138 On the other hand, galectin-7 induces 
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chemoresistance in breast cancer cells via impairing p53139 or via 
mutant p53-induced galectin-7 expression.140
Galectin-8 is expressed by various ovarian and breast cancer 
cell lines;141 however, only one study reported that breast cancer 
tissues constitute the only group of tissue to exhibit a higher im-
munohistochemical galectin-8 expression in the malignant, as 
opposed to the benign, tumors.142
Galectin-9 can be detected in normal epithelium and endo-
cervical glands, and it has decreased expression in cervical in-
traepithelial neoplasia and SCC. High-grade intraepithelial le-
sions express less galectin-9 than low-grade lesions. Unexpectedly, 
galectin-9 expression is higher in well-differentiated SCC com-
pared to moderate or poorly differentiated SCCs. These results 
imply the involvement of galectin-9 in the differentiation of cer-
vical cancer cells.143,144 Recently, galectin-9 has been implicated 
as a prognostic factor in breast cancer.145 The various roles of ga-
lectin-9 in tumorigenesis, including the participation in apopto-
sis, cell cycle control, adhesion, aggregation, migration, invasion, 
metastasis, angiogenesis, and immune escape, have recently been 
summarized in a review.146
Galectins in tumor invasion
The invasive and metastatic phenotype of cancer cells is pre-
sumably associated with a specific pattern of expression of cell 
adhesion molecules that allows for crossing through the base-
ment membranes and creating distant metastases. Emerging data 
demonstrate the role of galectins in metastasis events, although 
the data is conflicting, possibly due to the various effects that ga-
lectins may have according to the microenvironmental and phys-
icochemical changes.
Galectin-1, a laminin-binding molecule, may contribute to the 
invasiveness of cancer cells, since higher galectin-1 binding to 
cancerous epithelial cells was observed in stage III/IV endome-
trial carcinomas than in lower stage tumors.102,147 Indeed, the 
down-regulation of galectin-1 by siRNA results in the inhibi-
tion of cell growth, proliferation and invading ability of various 
cervical cancer cell lines.107
Galectin-3, when localized to the cell surface, is involved in 
Thomsen-Friedenreich antigen (Galβ1-3GalNAcα1 disaccharide)-
dependent homotypic cell adhesion and heterotypic cancer cell-
endothelial cell contact.148,149 Therefore, the decreased expression 
of this lectin could reflect the ability of cancer cells to detach 
from each other before invasion. Nuclear and cytoplasmic pres-
ence of galectin-3 implies that its localization and phosphoryla-
tion status is correlated with the proliferation status of the 
cells.150 All aspects of this topic have been reviewed elsewhere.151
Galectin-7 is also involved in the regulation of tumor growth 
and invasion. A recent in vitro study in human cervical SCC cell 
lines revealed that knocking down galectin-7 enhances tumor 
cell invasion and tumor cell viability against paclitaxel-induced 
apoptosis likely through increasing the matrix metallopeptidase 
(MMP)-9 expression and activating the phosphoinositide 3-ki-
nase/Akt signaling pathway.152 However, more studies demon-
strated that the expression of MMP-9 is increased by galectin-7 
in cervical or ovarian cancer cell lines through the p38 mitogen 
activated protein kinase signaling pathway or mutant p53, re-
spectively, resulting in increased cell invasion.153,154 In accord 
with this earlier study, high expression levels of galectin-7 are 
found exclusively in high-grade breast carcinomas; in a preclini-
cal mouse model of breast cancer, high expression of galectin-7 
significantly increases the ability of cancer cells to metastasize to 
lung and bone.155
Galectins in tumor angiogenesis
Galectin-3 is involved in tumor angiogenesis and invasion, as 
vascular endothelial growth factor C (VEGF-C)-mediated nucle-
ar factor kB signaling pathway promotes invasion of cervical 
cancer cells via VEGF-C–enhanced interaction between VEGF 
receptor-3 and galectin-3.156 Moreover, the cleavage of galectin-3 
and its subsequent release into the tumor microenvironment 
leads to breast cancer angiogenesis and progression as supported 
by the findings with BT-549-H(64) cells, in which galectin-3 in-
creases chemotaxis, invasion and cancer cell–endothelial cell in-
teractions resulting in angiogenesis and 3D morphogenesis. It is 
suggested that this in vitro angiogenic activity of galectin-3 is re-
lated to its ability to induce the migration of endothelial cells.157 
An in vivo study in immunocompromised mice transplanted 
with human breast cancer cells that overexpress galectin-3 showed 
increased density of capillaries surrounding the tumors, support-
ing that galectin-3 secreted by tumor cells induces angiogene-
sis.158
In addition, endothelial cells also express several galectins (-1, 
-3, -8, and -9) that may regulate tumor angiogenesis. For exam-
ple, galectin-9 splice variants are expressed by endothelial cells, 
and their expression is regulated during endothelial cell activa-
tion. It is suggested that galectin-9 is possibly involved in at-
tracting various immune cells (e.g. dendritic cells, DCs), which 
release angiogenic growth factors like VEGF, and its altered ex-
pression in the endothelium may interfere with a proper anti-tu-
mor immune response.146 Additional data that has started to 
emerge on the role of galectins in tumor angiogenesis is reviewed 
elsewhere.15 
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Galectins in tumor immune tolerance
Studies published to date mainly address the involvement of 
galectin-1 in tumor immune escape. Galectin-1 is involved in 
CD4+CD25+Foxp3+ Treg cell104 and tolerogenic DC activa-
tion, which may contribute to immune escape of tumor cells.159 
Th1 cells are important in anti-tumor immune responses160 in 
all cancer types, and galectin-1 induces the selective apoptosis of 
Th1, Th17, and Tc lymphocytes in mice161 and humans.25 Of 
note, anti–galectin-1 antibody treatment in combination with 
cell therapy in a cervical cancer mouse model is more effective 
than the treatment with tumor infiltrating lymphocytes alone.162 
This shows that inhibition of galectin-1 results in decreased im-
mune escape of tumor cells. In addition, galectin-1 silencing in 
a breast cancer mouse model results in a marked reduction in 
tumor growth and lung metastases.104 These results suggest that 
galectin-1 blockade may be a good therapeutic approach, and 
further aspects on the roles of galectin-1 in tumor formation and 
progression are reviewed elsewhere.163
Extracellular galectin-3 and galectin-7 induces apoptosis of T 
cells and peripheral blood mononuclear cells after binding to cell 
surface glycoconjugate receptors through carbohydrate-depen-
dent interactions.154,164 In the case of galectin-3, CD7 and CD29 
are identified as its apoptosis-inducing receptors. Furthermore, 
galectin-3–negative cell lines are significantly more sensitive to 
exogenous galectin-3 than those expressing this lectin. This sug-
gests crosstalk between the anti-apoptotic activity of intracellular 
galectin-3 and the pro-apoptotic activity of extracellular galec-
tin-3, providing a new insight for the immune escape mecha-
nisms of cancer cells.
Galectin-9 has immunosuppressive activity similar to galec-
tin-1;146 however, its role in tumor immune escape remains large-
ly unexplored. Galectin-9 suppresses Th17 cell differentiation 
and induces the apoptosis of Th1 and Tc cells, while it enhances 
CD4 + CD25 + Treg cell differentiation, suggesting immunosup-
pressive functions of this lectin. On the other hand, galectin-9 
was shown to induce the expansion of DCs and the subsequent 
potentiation of natural killer (NK) and Tc cell–mediated anti-
tumor immunity in melanoma and sarcoma models, respectively, 
showing that galectin-9 may have various effects on immune es-
cape.146
Galectins implicated as blood biomarkers of tumors
A few studies have focused on determining the concentrations 
of certain galectins (-1, -2, -3, -4, -8, -9)159,165,166 or galectin li-
gands167 in the sera of healthy people and cancer patients. The se-
rum concentrations of galectin-2, -3, -4, and -8 were up to 31-
fold higher in patients with breast cancer than in controls, in 
particular those with metastasis.166 It is important, since the pres-
ence of galectin-3 promotes cancer cell-endothelium adhesion in 
vitro via the interaction with the T antigen on cancer-associated 
mucin 1. In addition, galectin-2, -4, and -8 induce endothelial 
secretion of pro-inflammatory cytokines and chemokines in vitro, 
leading to the expression of endothelial cell surface adhesion 
molecules, and consequently increase cancer-endothelial adhe-
sion and endothelial tube formation.159
Serum from breast cancer patients also contains an almost 
two-fold higher concentration of galectin-1 ligand glycopro-
teins.167 The most abundant ones are α-2-macroglobulin, IgM 
and haptoglobin. In accordance, galectin-1–bound and non-
bound haptoglobin uptake was also analyzed, and a dramatic dif-
ference was found in intracellular targeting, with the galectin-1 
non-binding fraction targeted into lysosomes, while the galec-
tin-1 binding fraction targeted into larger, galectin-1–positive 
granules. This suggests a major regulatory step in the scavenging 
of hemoglobin by haptoglobin, which can be altered in cancer.167
Galectin-3 concentrations in urine of various (e.g. breast, cer-
vical, and ovarian) cancer patients and healthy controls showed a 
strong correlation between the stages of the disease and galec-
tin-3 concentration.168
GALECTINS IN PREGNANCY
Pregnancy poses a substantial challenge to the maternal im-
mune system. The semi-allogeneic fetus, placenta and chorioam-
niotic membranes continuously interact with maternal immune 
cells in the uterus, which is an immune privileged site,169 and those 
in the maternal circulation.170 During implantation and placen-
tation, there is a continuous immune recognition and modulation 
of the maternal immune system by trophoblasts at the maternal-
fetal interface.171-174 Moreover, there is a continuous deportation 
of fetal cells and trophoblastic debris into the maternal circula-
tion, which leads to microchimerism and an increase in systemic 
inflammation in the mother during pregnancy.175-179 Therefore, 
normal pregnancy is associated with a mild inflammatory state, es-
pecially by neutrophils of the innate immune system.180,181 This is 
significantly pronounced in preeclampsia, where the activation 
state of neutrophils is higher than in sepsis.182,183 Overtly activat-
ed neutrophils are also implicated in recurrent fetal loss or bacte-
rially induced abortions.181 It was also revealed that other great 
obstetrical syndromes (e.g. intrauterine growth restriction [IUGR] 
and preterm labor) are also associated with various changes in 
the phenotypes as well as the behavior of maternal peripheral 
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blood leukocytes and systemic inflammation.183-186 Since several 
galectins are expressed at the maternal-fetal interface, the site of 
contact between maternal and fetal cells that varies among dif-
ferent species,171,187-190 they are proposed to promote maternal-fe-
tal immune tolerance and regulate local and systemic inflamma-
tion and infection.10,16,17,26,27 Indeed, changes in the expression of 
galectins23,32-38 have been reported in the great obstetrical syn-
dromes (e.g. preterm labor, preeclampsia),191 which are related to 
local and/or systemic inflammation and infection, and are respon-
sible for most perinatal mortality and morbidity.192-205
Galectin expression at the maternal-fetal interface in normal 
pregnancy
The human maternal-fetal interfaces dynamically change dur-
ing gestation.190 First, the syncytiotrophoblast is in direct con-
tact with maternal cells in the decidua for a few days post-im-
plantation and then with cells in the intervillous space. The latter 
is also the site of the interaction between the syncytiotrophoblast 
and maternal blood cells by the end of the first trimester, while 
invasive extravillous cytotrophoblasts in the placental bed and 
trophoblasts in the chorion laeve come into contact with mater-
nal cells in the decidua.190 In this dynamic context, the expression 
of several galectins is also spatio-temporally regulated during de-
velopment (Fig. 3).8 Galectin-1, -3, and -9 are broadly expressed 
during human and mouse embryogenesis, suggesting that they 
may play a role in embryo development in mammals.8 Despite 
that, galectin-1 or galectin-3 knock out (KO) mice are viable,206 
possibly due to the redundancy in galectin functions.8 In addi-
tion, galectin-1, -3, -8, -9, -13, -14, and -16 are also strongly ex-
pressed at the maternal-fetal interface in various mammals, some 
in a developmentally regulated fashion.16,18,19,21,23,27,32-34,39
For example, galectin-1 expression is strong in the differentiated 
syncytiotrophoblast but not in the cytotrophoblast during first 
and third trimesters,19,207,208 and its expression in the extravillous 
trophoblast is developmentally regulated during the first-trimes-
ter.19,209 This latter phenomenon is also true for galectin-3, which 
also localizes to villous cytotrophoblasts.19,208 Galectin-4 has weak-
er placental expression,27 which is down-regulated during tropho-
blast differentiation in rats.210 Galectin-8 has expression in villous 
and extravillous trophoblasts,39 while galectin-9 is mainly located 
in the decidua.16 RNA and protein evidence have shown that ga-
lectins in the chromosome 19 cluster (-13, -14, -16, and -17) are 
predominantly expressed by the syncytiotrophoblast but not by 
the underlying cytotrophoblasts.27,28,31,33,46,58 This is supported by 
galectin-13 immunolocalization to the multinucleated luminal 
trophoblasts within converted decidual spiral arterioles in the 
first trimester.28 A recent study demonstrated that the expression 
of galectin-13, -14, and -16 is related to the differentiation and 
syncytialization of the villous trophoblast,72 which is important 
in the production of placental hormones and immune proteins 
to control fetal development and immune tolerance.189,211,212 In 
vitro assays demonstrated that the expression of these galectins is 
related to syncytium formation induced by cAMP.72 Interesting-
ly, the promoter evolution and the insertion of a primate-specific 
transposable element into the 5’ untranslated region of an ances-
tral galectin gene introduced several binding sites for transcrip-
tion factors fundamental in syncytiotrophoblastic gene expres-
sion, leading to the gain of placental expression of these 
chromosome 19 cluster galectins.72,213 Of note, DNA methyla-
tion also regulates the developmental expression of these genes72 
similar to other galectins.214 Of interest, galectin-1, -7, -9, -13, 
-14, -16, and -17 are also expressed in the chorioamniotic mem-
branes, but the developmental aspects of their regulation at this 
site have not yet been revealed.16,27,34,37,38
Galectins in embryo implantation
Embryonic implantation can be considered a pro-inflammato-
ry response in the decidua, which involves the chemotaxis of leu-
kocytes and their active participation in the regulation of im-
plantation via secreted immune and angiogenic factors.215-218 
Decidual cell-derived factors also have a key role in implanta-
tion.219 Of importance, several galectins are expressed by the 
uterine endometrium and decidua in mammals and are strictly 
regulated by sex steroids.18,22,220-222 The peak expression of these 
galectins coincides with the implantation time window; there-
fore, their possible roles in blastocyst attachment and in the reg-
ulation of immune cell functions during implantation have been 
implicated (Fig. 3).18,21,22
For example, a temporal expression change of galectin-1, de-
pendent on estrogen and progesterone, has been observed during 
the estrus cycle in mice.10,18 In humans, the expression of galec-
tin-1, -2, -3, -4, -8, -9, and -12 is described in the endometri-
um21,22,98,113,223-225 where galectin-1 and galectin-3 are highly ex-
pressed during the implantation time window.22,221 Galectin-3 
expression is increased in glandular epithelial cells in the secre-
tory phase, while galectin-1 expression is increased in stromal 
cells in the late secretory phase and further increased in the de-
cidua.22 Interestingly, galectin-1 is also expressed in the trophec-
toderm and inner cell mass of human pre-implantation stage 
embryos, where it may be involved in the attachment to the 
uterine epithelium.226 In spite of the identification of galectin-3 
in trophoblasts, its role in implantation has not been well de-
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Data in humans and mice support that galectin-9 is also in-
volved in implantation. In mouse models, galectin-9 is associat-
ed with cell-to-cell interactions and the establishment of an im-
muno-privileged local environment for implantation and early 
fetal development as well as the mediation of decidual cell mi-
gration and chemotaxis.223 In humans, galectin-9 is expressed by 
the endometrial glandular epithelial cells during the implanta-
tion time window as well as by the human decidua during early 
pregnancy.21 Electron microscopy clarified its localization on the 
apical projections of the human endometrial epithelium called 
uterodomes,223 which are membrane projections that exclusively 
feature the receptive endometrium during the implantation 
time window. The contribution of galectin-9 to the develop-
ment of pregnancy is supported by the observation that normal 
pregnancy and cases of spontaneous abortions differ significantly 
in terms of endometrial galectin-9 splice variant profiles in both 
mice and humans.227
Galectins in trophoblast invasion
A growing body of evidence suggests that human galectins 
play key roles in placentation events beyond implantation. For 
example, galectin-1, -3, and -8 are expressed in the extravillous 
trophoblast in the first trimester19,39 throughout the invasive 
Fig. 3. Physiological aspects of galectins at the maternal-fetal interface. The figure represents multiple roles of galectins in implantation, an-
giogenesis, maternal-fetal immune tolerance and trophoblast invasion. (A) Embryo implantation. (B) Formation of primary villi by proliferative 
cytotrophoblasts. (C) Formation of tertiary villi, placental angiogenesis, extravillous trophoblast invasion and spiral artery remodeling. AE, am-
niotic epithelium; CCT, cell column trophoblast; DC, dendritic cell; DF, decidual fibroblast; EB, embryoblast; EC, endothelial cell; ECM, extra-
cellular matrix; EM, extraembryonic mesoderm; eCTB, endovascular cytotrophoblast; GC, giant cell; ICM, inner cell mass, iCTB, interstitial 
cytotrophoblast; LUE, luminal uterine epithelium; L, lacunae; MMP, matrix metalloproteinase; NK, natural killer; pF, placental fibroblast; PS, 
primitive syncytium; pV, placental vessel; SA, spiral artery; S, syncytium; SMC, smooth muscle cell; TE, trophectoderm; UG, uterine gland; 
uNK, uterine NK cell; UV, uterine vessel; vCTB, villous cytotrophoblast. Cartoons are adapted from Knofler and Pollheimer. Front Genet 
2013; 4: 190, under the terms of the Creative Commons Attribution License.217
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pathway of trophoblast differentiation.212,217,228 These galectins 
are expressed in extravillous trophoblast cell columns, where 
they actively deposit extracellular matrix and can bind to major 
structural glycans of the placental bed (e.g. fibronectin and lam-
inin).8,19,39,229 Thus, galectin-1, -3, and -8 may play a role in the 
organization of the extracellular matrix and the modulation of 
cell adhesion in the cell columns.19,39 In addition, galectin-1 and 
-3 may have a role in the regulation of the extravillous tropho-
blast cell cycle since they are absent from the differentiated, non-
proliferating, interstitially migrating, highly invasive cytotro-
phoblasts (Fig. 3).19
Not only the expression pattern of galectin-1 in the first tri-
mester placenta but also the findings that blocking galectin-1 
substantially abrogates migration of primary trophoblasts and 
HTR8/SVneo cells cultured in matrigel19,209 suggest that galec-
tin-1 modulates the invasive pathway of trophoblast differentia-
tion and enhances trophoblast invasiveness. Extravillous tropho-
blastic galectin-319,208 may interact between cell and extracellular 
matrix components, modulating adhesive interactions and im-
mune reactions as observed in a murine model.230
In the case of galectin-13 (PP13), a different mechanism is 
proposed to promote trophoblast invasion.28 Galectin-13 is se-
creted by the syncytiotrophoblast to the maternal circulation, 
from where it is transferred into the decidua in the first trimes-
ter, coinciding with the time of early trophoblast invasion. Inter-
estingly, galectin-13 forms crystal-like aggregates in the decid-
ua, where it attracts, activates and kills maternal immune cells, 
diverting them from spiral arterioles and invading trophoblasts.28 
In this manner, PP13 may serve to establish a decoy inflamma-
tory response, sequestering maternal immune cells away from the 
site of extravillous trophoblast spiral artery modification.
Galectins in maternal-fetal immune tolerance
In eutherian mammals multiple immune mechanisms exist 
which support the establishment and maintenance of immuno-
logical privilege in the pregnant uterus, as well as antigen-spe-
cific, local and systemic maternal-fetal tolerance.10,26,27,171-174,192 
These mechanisms are strongly affected by the type of placenta-
tion and the interactions between fetal trophoblasts and mater-
nal immune cells at the maternal-fetal interfaces.171,187,189 In this 
regard, it is important to note that galectins are also expressed 
by maternal immune cells, which infiltrate the decidua and play 
key roles in mammalian pregnancies (Fig. 3).20,25,51,70,231
For example, galectin-1 is strongly expressed by uterine natu-
ral killer (uNK) cells compared to peripheral blood NK cells.20 
These CD56+ galectin-1+ uNK cells comprise ~70% of maternal 
leukocytes at the implantation site, promote angiogenesis and 
trophoblast invasion20,171 and are pivotal for the maternal adapta-
tion to pregnancy.232 Galectin-1, secreted by human uNK cells, 
induces apoptosis of activated decidual T cells,25 which is sup-
ported by data indicating that galectin-1 can selectively induce 
apoptosis of Th1 and Th17 cells25,63 and contribute to maternal 
immune-tolerance to the semi-allogeneic fetus.10,25,26 In addi-
tion, galectin-1 is among the immunosuppressive molecules se-
creted by villous trophoblasts, which were identified by a pro-
teomics study and found to inhibit T lymphocyte proliferation 
and adaptive immune responses.69 The villous trophoblast se-
cretes other galectins, expressed from the chromosome 19 galec-
tin cluster (-13, -14, and -16), which induce the apoptosis of ac-
tivated T cells, and thus, are assumed to exert special 
homeostatic and immunobiological functions at the maternal-
fetal interface.16,27
As in vivo evidence for the pivotal functions of human galec-
tin-1, a proteomics study identified it to be down-regulated in 
villous placenta in early pregnancy loss, reflecting abnormalities 
in the support for the maintenance of pregnancy.23 Other in vivo 
evidence comes from a mouse model of stress-induced fetal loss 
in which the decidual expression of galectin-1 decreased, and 
these mice, similar to galectin-1 KO mice, had a higher rate of 
fetal loss in allogeneic pregnancies.10 This effect was reversed by 
the administration of recombinant galectin-1 and also by pro-
gesterone treatment, supporting the progesterone-dependent 
regulation of decidual galectin-1 expression. Galectin-1 treat-
ment also prevents the drop in progesterone and progesterone-
induced blocking factor serum concentrations in stressed ani-
mals, suggesting a synergistic effect of galectin-1 and progesterone 
in pregnancy maintenance.10 It was also elucidated that galec-
tin-1 exerts its immune modulatory effect through the induc-
tion of tolerogenic DCs, which in turn trigger the expansion of 
interleukin-10 expressing CD4+ CD25+ Treg cells in vivo.10 Subse-
quently, it was determined that Treg cells, which normally ex-
pand during pregnancy and suppress the maternal allogeneic re-
sponse directed against the fetus,187 also overexpress galectin-10, 
which has an important role in suppressive functions.70,231
The galectin-9/TIM-3 (T-cell immunoglobulin domain and 
the mucin domain 3) pathway has been recognized as central in 
the regulation of Th1 immunity and tolerance induction.233,234 
Very recently, galectin-9 was also implicated in the regulation of 
uNK cell function and the maintenance of normal pregnancy235 
as galectin-9, secreted by human trophoblast cells, induces the 
transformation of peripheral NK cells into uNK-like cells via 
the interaction with TIM-3. In addition, a decreased number of 
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TIM-3+ uNK cells was detected in human miscarriages and abor-
tion-prone murine models, and a Th2/Th1 imbalance was de-
tected in TIM-3+ uNK cells in human and mouse miscarriages, 
suggesting the importance of the galectin-9/TIM-3 pathway.235 
Moreover, Treg cells increase their galectin-9 expression with 
advancing gestational age in accord with the increasing galec-
tin-9 concentrations in maternal blood, suggesting that galec-
tin-9 expressing Treg cells may have important roles in the 
maintenance of pregnancy.236
Galectins in placental angiogenesis
Aside from modulating the immune system and trophoblast 
invasion, human galectins have been implicated in key roles in 
angiogenesis (Fig. 3). This is not surprising in light of the pivot-
al role of galectin-glycan interactions in angiogenesis237 and the 
angiostimulatory roles of several galectins reviewed elsewhere.14 
The most studied galectin, with respect to placental angiogene-
sis, is galectin-1. When this lectin is added exogeneously in a 
rodent model of reduced angiogenesis, it enhances the produc-
tion of pro-angiogenic factors (e.g. angiogenin, heparin-binding 
epidermal growth factor, and fibroblast growth factor-basic) and 
matrix metallopeptidases (MMP-3, MMP-8, and MMP-9) to 
promote normal vascular development, to rescue implantation 
and to support healthy placentation.238 Galectin-1 acts via the 
NRP-1–VEGF–VEGF-R2 signaling pathway,239,240 which is 
important in promoting angiogenesis during implantation, de-
cidualization and placentation.241,242 Galectin-1 binding to neu-
ropilin-1 promotes VEGF–VEGF-R2 interactions, and conse-
quently, endothelial cell migration and adhesion,239,241,243 and 
these effects can be blocked by an NRP-1 neutralizing antibody, 
which inhibits VEGF–VEGF-R2 signaling.238,240
Although several other galectins (-3, -8, and -9) have been 
implicated in angiogenesis and endothelial cell biology,14 their 
involvement in placental angiogenesis has not yet been elucidat-
ed. The effect of galectin-13 has recently been tested on rat vas-
culature, and it was found that recombinant galectin-13 reduces 
blood pressure and increases utero-placental perfusion in vivo, 
while it promotes vasodilation in isolated arteries in vitro.244,245
Galectins in local inflammation in the womb
Term parturition is characterized by local pro-inflammatory 
changes in the decidua and chorioamnion, which play funda-
mental roles in the initiation of labor and myometrial contrac-
tions.37,246-249 Evidence from microarray studies have shown that 
galectins may also play a role in pathways leading to term labor 
as galectin-7 is up-regulated in the amnion in oxytocin-induced 
labor, and galectin-9 is down-regulated in the chorion at the site 
of rupture (Fig. 4).37
Preterm parturition is a syndrome that has many etiologies, 
predominantly those associated with intra-amniotic infection 
and inflammation.193,205,250 The pathways initiated in preterm 
parturition are different from those in term labor, whereas the 
terminal pathway of cervical effacement and dilatation, chorio-
decidual, as well as myometrial activation, are shared between 
the two.193,205,246,250 Interestingly, proteomics studies show that 
galectin-1 is upregulated in the fetal membranes in preterm par-
turition,38 reflecting heightened local inflammation.
Preterm premature rupture of the membranes (PPROM) is a 
syndrome in which approximately 32%–75% of the cases are 
associated with microbial invasion of the amniotic cavity.193,195,196 
To date, only galectin-1 expression has been studied in PPROM 
using detailed gene and protein expression profiling;34 it is in-
creased in the chorioamniotic membranes in patients with histo-
logic chorioamnionitis, but not in those without this condition. 
Galectin-1 expression is increased34 in a temporal and spatial 
fashion in amnion epithelial cells, maternal neutrophils and cho-
rioamniotic macrophages and myofibroblasts251 with advancing 
inflammation. Since galectin-1 is associated with the up-regula-
tion of genes encoding for MMPs in DCs,252 it has been pro-
posed that the overexpression of galectin-1 in the chorioamniotic 
membranes may be the link between inflammation, tissue re-
modeling, and membrane weakening, which may contribute to 
the membrane rupture.34 Moreover, the increased expression of 
galectin-1 by chorioamniotic macrophages upon inflammation 
suggests a role for galectin-1 in the active barrier functions of 
the membranes, protecting the fetus from bacterial infection and 
promoting the recognition and phagocytic removal of invading 
maternal neutrophils.34 This hypothesis is supported by findings 
that (1) activated macrophages are present in the fetal mem-
branes in association with fetal inflammatory response upon in-
fection,253-255 (2) the chorioamniotic membranes have antimicro-
bial properties,256 (3) galectin-1 expression is up-regulated in 
activated macrophages257 where it regulates macrophage effector 
functions,258 (4) galectin-1 decreases macrophage inducible ni-
tric oxide synthase expression and inhibits lipopolysaccharide-
induced NO metabolism,259 and (5) it regulates the cell surface 
expression of FcγRI.258
Galectins in inflammatory conditions in the neonate
Due to galectins’ roles in immune responses, their relevant 
roles in term and preterm parturition in the neonate have also 
been investigated, mainly regarding galectin-1 and galectin-3 
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(Fig. 4).260-262
In term parturition, in spite of the physiological systemic in-
flammation in the mother at the time of normal delivery, cord 
blood plasma contains more galectin-3 than maternal plasma, 
regardless of the delivery mode.262 In addition, cord blood neu-
trophils show priming in comparison to maternal neutrophils by 
responding to galectin-3 with reactive oxygen species (ROS) pro-
duction, suggesting that inflammatory stimuli associated with 
labor promotes neutrophils to develop a reactive phenotype with 
extensive priming features.262 Indeed, when cord blood leuko-
cytes are stimulated by invasive bacteria, there is an induction of 
galectin-3 expression, suggesting its importance for innate im-
munity in the neonate.260 Although galectin-1 is also expressed 
in cord blood, lymphocytes expressing galectin-1 were not deter-
mined to have a major role in immune reactivity in cord blood.263
In preterm parturition, the earlier preterm birth occurs, the 
higher the rate of intra-amniotic infection and inflammation.193 
Since 5%–13% of pregnancies are affected by preterm parturi-
tion,194 the resulting severe complications (i.e. intraventricular 
hemorrhage, cystic periventricular leukomalacia, bronchopul-
monary dysplasia [BPD], and cerebral palsy) have disastrous 
short-term and life-long impacts on the neonate, and the health-
care and social impacts are immense.193,205 In regard to these, ga-
lectin-3 concentrations are elevated in the cerebrospinal fluid of 
infants suffering from birth asphyxia, and even higher in those 
with abnormal outcomes.261 Since galectin-3 is produced by ac-
tivated microglia/macrophages and activates NADPH oxidase, 
leading to neurotoxic production of ROS and contributing to 
hypoxic brain injury in an animal model,264 it has been proposed 
to serve as a marker for abnormal outcomes.261 In addition, in a 
small preliminary study, galectin-3 concentrations in tracheal as-
pirates of premature infants tended to be elevated in the first 
week of life in those who later developed BPD (Staretz et al., 
personal communication).
Fig. 4. Galectin expression at the maternal-fetal interface. The figure represents the maternal-fetal interfaces where maternal and fetal cells 
appose each other from the end of the first trimester of human pregnancy. The villous syncytiotrophoblast (depicted with gold) is bathed in 
maternal blood, whereas invasive extravillous trophoblasts in the placental bed (depicted in red) and chorionic trophoblasts in the fetal mem-
branes (depicted in red) are in contact with maternal cells in the decidua (depicted in dark blue). The differential expression of galectins is de-
picted according to the interface where observed in normal pregnancy and in pregnancy complications. Sy., syndrome, Cartoon was adapt-
ed from Than et al. Trends Endocrinol Metab 2012; 23: 23-31, with permission of Elsevier.16
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IUGR is one of the most heterogeneous syndromes in obstet-
rics; it is associated with fetal malformations and chromosomal 
abnormalities, as well as maternal autoimmune disorders and 
placental dysfunction resulting from poor implantation, making 
the understanding of an IUGR fetus a challenge. In addition, 
neonates may be small-for-gestational age (SGA) due to a nor-
mal condition in short-stature couples.265 Of interest, a recent 
report showed that galectin-3 concentrations in cord blood have 
a positive correlation with gestational age, and SGA neonates 
have higher concentrations of galectin-3 than those that are ap-
propriate for gestational age,260 which may be a sign of an in-
flammatory condition.
Galectins in preeclampsia, a systemic inflammatory state
Based on the above data, it is not surprising that galectins have 
been implicated in the development of preeclampsia, a syndrome 
with impaired trophoblast invasion, an anti-angiogenic state and 
an exaggerated maternal systemic immune response.190,266 Pre-
eclampsia is a severe complication of pregnancy, which affects 
5%–7% of pregnant women and is a leading cause of maternal 
and perinatal morbidity and mortality.267,268 It also confers a high 
risk to the mother and fetus for metabolic and cardiovascular dis-
eases later in life.269-272 Preeclampsia is a syndrome with a spec-
trum of phenotypes, which may present at various gestational 
ages, with different degrees of severity at clinical onset, and also 
with or without the involvement of the fetus.272-274
It is a multi-stage disease that has placental origins190,275-277 due 
to the failure of extravillous trophoblast invasion into the uterine 
tissues278,279 and impaired villous trophoblastic syncytializa-
tion.72,280,281 Subsequent rheological changes in uterine blood 
flow, metabolic changes, and ischemic stress of the villous placen-
ta lead to the liberation of anti-angiogenic molecules, highly in-
flammatory placental debris, and cell-free fetal DNA that may 
also be pro-inflammatory and cause an exaggerated maternal 
systemic inflammatory response, anti-angiogenic conditions and 
end-organ damage.179,181,190,192,271,275-277,282-291 Other, less severe 
pathologies are also implicated that result in the terminal path-
way of systemic inflammation and an anti-angiogenic state.292 
Importantly, several members of the galectin family have been 
implicated in the development of various stages of this syn-
drome (Fig. 4).
Impaired extravillous trophoblast invasion
Indirect evidence of galectin involvement is the up-regulation 
of galectin-1 and -3 in the extravillous trophoblasts in the pla-
cental bed during preeclampsia and HELLP syndrome,38,158 
which is associated with the failure of extravillous trophoblast 
invasion.32 It was also observed that low galectin-13 expression 
is associated with deficient trophoblast invasion, failure of spiral 
arteriole conversion, and the development of preeclampsia.28
Impaired villous trophoblastic syncytialization
Galectin-13 and galectin-14 mRNA expression is decreased 
in the syncytiotrophoblast in preeclampsia associated with or 
without HELLP syndrome at the time of clinical onset, pre-
dominantly in the early-onset forms.28,33,72 Importantly, de-
creased galectin-13 mRNA expression can be detected as early 
as the first trimester in laser captured specimens of chorionic 
villous trophoblasts as well as decreased galectin-13 protein and 
mRNA concentrations in first trimester maternal serum sam-
pled from patients destined to develop preeclampsia.36 This 
phenomenon possibly reflects abnormal villous trophoblast syn-
cytialization starting from early pregnancy and may be one of 
the earliest placental indicators for the subsequent development 
of preeclampsia. A recent study72 revealed that GCM1 and 
ESRRG, two transcription factors that regulate villous tropho-
blastic syncytialization and metabolic functions, are down-reg-
ulated in the placenta in preeclampsia. Functional and evolu-
tionary evidence also implicates these two factors in regulating 
trophoblastic expression of chromosome 19 galectin cluster 
genes. This is supported by the observation of decreased 
GCM1-mediated trophoblast fusion in impaired galectin gene 
expression in preeclampsia.72 Furthermore, the differential 
methylation of LGALS13 and LGALS14 is also found in the 
villous trophoblast in preterm preeclampsia, suggesting that 
potential additional disease-mechanisms may account for the tro-
phoblastic pathology in preterm preeclampsia.72
Villous placental stress
Galectin-1 and -8 are overexpressed in the villous trophoblast 
in preeclampsia and HELLP syndrome,32,35 where increased pla-
cental stress occurs preceding exaggerated maternal systemic in-
flammation.275,276,290,293,294 It is possible that galectins may func-
tion as “alarmins” in this condition.12,35 Alarmins are endogenous 
danger signals secreted by activated cells via non-classical path-
ways or released from necrotic cells, which signal tissue damage 
and contribute to the activation and/or resolution of immune re-
sponses.66 Galectin-13 may also be considered a placental alarm-
in since it is excessively secreted or shed from the syncytiotro-
phoblast at the time of the clinical onset of preeclampsia and 
HELLP syndrome.33,64 Interestingly, the syncytiotrophoblast mi-
crovillous membrane and microvesicles, which are shed from the 
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syncytiotrophoblast, stain strongly for galectin-13, suggesting 
that the increased release of galectin-13–positive microvesicles 
from the syncytiotrophoblast may lead to elevated maternal se-
rum galectin-13 concentrations when the clinical symptoms ap-
pear.33,46
Anti-angiogenesis
Placental and maternal blood galectin-1 expression is down-
regulated in patients with early-onset preeclampsia, and Lgals1 
KO mice exhibit preeclampsia-like symptoms, probably due to 
the inhibition of pro-angiogenic effects of galectin-1.238 Moreover, 
blocking galectin-1–mediated angiogenesis with anginex, a syn-
thetic peptide, also promotes preeclampsia-like symptoms in mice 
and inhibits human extravillous trophoblast functions in vitro.238,295
Maternal systemic inflammation
The number of galectin-1–expressing NK cells and Treg cells 
is decreased in preeclampsia,51,296,297 which may reflect a failure 
of immune tolerance in this syndrome.298 Recently, the involve-
ment of galectin-9 and its TIM-3 ligand has been implicated in 
maternal systemic inflammation in preeclampsia.299 In this re-
gard, decreased TIM-3 expression by T cells, cytotoxic T cells, 
NK cells, and CD56dim NK cells, as well as increased frequen-
cy of galectin-9+ peripheral lymphocytes, is detected in women 
with early-onset preeclampsia, suggesting that the impairment 
of the galectin-9/TIM-3 pathway can result in an enhanced sys-
temic inflammatory response including the activation of Th1 
lymphocytes in preeclampsia.299 
Galectins implicated as maternal blood biomarkers 
in obstetrical syndromes
Due to the dysregulation of some galectins at the maternal-fe-
tal interface and in maternal blood in various obstetrical syn-
dromes, investigations have been expanded on their possible val-
ue as diagnostic, predictive and prognostic biomarkers of these 
pregnancy complications. Most data is available for galectin-13, 
also known as PP13, which has been widely investigated by in-
ternational collaborative studies (Fig. 4).41-50,58 The changes in 
the expression patterns of galectin-13 in the placenta during 
gestation in normal and preeclamptic pregnancies, the fact that 
galectin-13 is expressed only in the placenta,27 and it is not de-
tected in non-pregnant patients (Madar-Shapiro et al., personal 
communication), make this galectin a suitable and promising 
first trimester maternal blood biomarker for the prediction of 
preterm preeclampsia. In addition, genetic studies found certain 
single nucleotide polymorphisms, including an exonic variant 
(221delT) in the LGALS13 gene, which may increase the risk 
for preterm labor and preeclampsia.300 Recent advancement in 
the field has also facilitated the study of the potential use of this 
galectin as a therapeutic drug for preeclampsia.244,245 The utiliza-
tion of other galectins as biomarkers has recently been started.
In the first trimester of pregnancy, there is a lower PP13 
mRNA content in maternal blood in preeclampsia compared to 
controls;301,302 however, the predictive value of the detected ma-
ternal blood PP13 mRNA species is currently limited due to 
the varying and low amounts of trophoblastic mRNA reaching 
the maternal circulation. Much more promising results were de-
rived from studies on maternal blood PP13 concentrations in 
the first trimester for the prediction of preeclampsia, which were 
analyzed by a recent meta-analysis.303 The results were pooled 
from 19 studies on singleton pregnancies, which were included 
in prospective or nested case-control studies or fully prospective 
studies in which a total of 16,153 pregnant women were tested 
for PP13 between 6 and 14 weeks of gestation.42-48,50,58,304-313 For 
all cases of preeclampsia, the mean detection rate (DR) for pre-
dicting preeclampsia was 47% (95% confidence interval [CI], 
43 to 65) at a 10% false-positive rate (FPR). For preterm pre-
eclampsia, the DR was 66% (95% CI, 48 to 78); for early-onset 
preeclampsia, the DR was 83% (95% CI, 25 to 100). For all cases 
of preeclampsia, the positive likelihood ratio (LR) [sensitivity/
(1-specificity)] was 5.82, while the negative LR [(1-sensitivity)/
specificity] was 0.46. For preterm preeclampsia, both of these in-
dices were better (positive LR, 6.94; negative LR, 0.34).
Of interest, the introduction of maternal ABO blood groups 
into the prediction model could improve the DRs for pre-
eclampsia, which can be explained by the differential binding of 
PP13 onto ABO blood group antigen-containing cell surfaces 
and the varying bioavailability of PP13 in maternal blood de-
pending on the ABO blood type.58 Moreover, the performance of 
the first trimester PP13 test could further be improved by the 
inclusion of PP13 into panels of multiple biomarkers (e.g. 
ADAM metallopeptidase domain 12 [ADAM12], pregnancy 
associated plasma protein A [PAPP-A], placenta growth factor 
[PlGF]),50,314 which is necessitated in light of the syndromic na-
ture of preeclampsia.48,314 In addition, risk predictions based on 
combining PP13 and uterine artery Doppler pulsatility index 
(PI) also showed increased prediction accuracy.42,44,304,306,314-316 
Moreover, the combination of PP13, Doppler PI, and maternal 
artery stiffness (MAP) increased the DR of preeclampsia to 93% 
for early-onset preeclampsia and to 86% for all cases of pre-
eclampsia at 10% FPR.49 This is in line with comprehensive risk 
algorithms based on combined multi-marker analysis of back-
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ground risks, MAP, Doppler PI, and a panel of blood biomarkers 
that can yield much higher predictive value and accuracy than 
individual markers,306 especially for early-onset (< 34 weeks) and 
preterm (< 37 weeks) preeclampsia. Therefore, the introduction 
of a broad biomarker panel for the evaluation of preeclampsia 
and other obstetrical syndromes in the first trimester is suggest-
ed in order to change antenatal care as formulated by the invert-
ed pyramid model of perinatal evaluation in pregnancy.317
In the second trimester of pregnancy, galectin-13 does not 
have much diagnostic or predictive value due to the sharp in-
crease in PP13 maternal blood concentrations in preeclampsia 
between the first and third trimesters compared to the moderate 
change in women with normal pregnancy.318 Interestingly, ga-
lectin-1 has recently emerged as a potential preclinical biomark-
er for preeclampsia since a prospective study detected decreased 
galectin-1 maternal blood concentrations and placental expres-
sion in early-onset preeclampsia compared to normal pregnancy 
in mid pregnancy.238 Of note, placental galectin-1 expression is 
increased in preterm and severe preeclampsia compared to nor-
mal pregnancy.35,238
In the third trimester of pregnancy, galectin-13 may have di-
agnostic significance for the clinical development of preeclamp-
sia according to a recent meta-analysis.318 This included eight 
clinical studies that contained third trimester maternal blood 
PP13 data from 2750 pregnant women.33,45,46,58,319,320 Maternal 
blood PP13 was higher in women who subsequently developed 
preeclampsia compared to unaffected women. The mean DR at 
10% FPR for all preeclampsia cases was 59.4% (95% CI, 49.7 
to 64.5), and for preterm preeclampsia was 71.7% (95% CI, 
60.3 to 75.3). Interestingly, the DR appeared to be related to 
the severity of the cases in a given study, showing that the higher 
the hypertension and proteinuria, the higher the third trimester 
PP13 in maternal blood. A combined algorithm of PP13, MAP 
and proteinuria yielded a 95% DR for preterm preeclampsia and 
85% for all preeclampsia at 5% FPR. The positive LR for all 
cases of preeclampsia was 5.94 and the negative LR was 0.45, 
providing an overall LR of 26.24. The positive LR for preterm 
preeclampsia was 7.17 and the negative LR was 0.31, providing 
an overall LR of 37.99. Therefore, the meta-analysis indicates 
that higher third trimester maternal blood PP13, among wom-
en who subsequently developed preeclampsia, reached clinical 
diagnostic levels.318
CONCLUSION
Galectins are an evolutionarily ancient family of lectins that 
have pleiotropic functions in the regulation of key biological 
processes. Galectins are pivotal in immune responses, angiogen-
esis, cell migration and invasion, and due to these functions, 
they have double-edged functions in shared and unique path-
ways of embryonic and tumor development. Recent advances fa-
cilitate the use of galectins as biomarkers in obstetrical syn-
dromes and in various malignancies, and their therapeutic 
applications are also under investigation.
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